Neurogene Stock Technical Analysis

NGNE Stock   17.38  0.38  2.24%   
As of the 17th of February 2026, Neurogene secures the Risk Adjusted Performance of (0.1), mean deviation of 3.57, and Standard Deviation of 4.71. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurogene, as well as the relationship between them. Please verify Neurogene market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Neurogene is priced some-what accurately, providing market reflects its recent price of 17.38 per share. Given that Neurogene has information ratio of (0.15), we recommend you to check Neurogene's last-minute market performance to make sure the company can sustain itself at a future point.

Neurogene Momentum Analysis

Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Neurogene, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to NeurogeneNeurogene's Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.

Neurogene Analyst Consensus

Target PriceConsensus# of Analysts
57.2Strong Buy7Odds
Neurogene current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Neurogene analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Neurogene stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Neurogene, talking to its executives and customers, or listening to Neurogene conference calls.
Neurogene Analyst Advice Details
Will Biotechnology sector continue expanding? Could Neurogene diversify its offerings? Factors like these will boost the valuation of Neurogene. Anticipated expansion of Neurogene directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neurogene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(4.10)
Return On Assets
(0.27)
Return On Equity
(0.42)
Understanding Neurogene requires distinguishing between market price and book value, where the latter reflects Neurogene's accounting equity. The concept of intrinsic value - what Neurogene's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neurogene's price substantially above or below its fundamental value.
It's important to distinguish between Neurogene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurogene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neurogene's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.

Neurogene 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neurogene's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neurogene.
0.00
11/19/2025
No Change 0.00  0.0 
In 3 months and 1 day
02/17/2026
0.00
If you would invest  0.00  in Neurogene on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Neurogene or generate 0.0% return on investment in Neurogene over 90 days. Neurogene is related to or competes with Lineage Cell, Ocugen, Fulcrum Therapeutics, Autolus Therapeutics, ADC Therapeutics, Benitec Biopharma, and Solid Biosciences. Neurogene is entity of United States. It is traded as Stock on NASDAQ exchange. More

Neurogene Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neurogene's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neurogene upside and downside potential and time the market with a certain degree of confidence.

Neurogene Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurogene's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neurogene's standard deviation. In reality, there are many statistical measures that can use Neurogene historical prices to predict the future Neurogene's volatility.
Hype
Prediction
LowEstimatedHigh
13.3917.3721.35
Details
Intrinsic
Valuation
LowRealHigh
15.6427.0631.04
Details
7 Analysts
Consensus
LowTargetHigh
52.0557.2063.49
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-1.06-1.05-1.03
Details

Neurogene February 17, 2026 Technical Indicators

Neurogene Backtested Returns

Neurogene has Sharpe Ratio of -0.0595, which conveys that the firm had a -0.0595 % return per unit of risk over the last 3 months. Neurogene exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neurogene's Standard Deviation of 4.71, risk adjusted performance of (0.1), and Mean Deviation of 3.57 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 2.18, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neurogene will likely underperform. At this point, Neurogene has a negative expected return of -0.24%. Please make sure to verify Neurogene's value at risk, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if Neurogene performance from the past will be repeated at some point in the near future.

Auto-correlation

    
  -0.01  

Very weak reverse predictability

Neurogene has very weak reverse predictability. Overlapping area represents the amount of predictability between Neurogene time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neurogene price movement. The serial correlation of -0.01 indicates that just 1.0% of current Neurogene price fluctuation can be explain by its past prices.
Correlation Coefficient-0.01
Spearman Rank Test-0.14
Residual Average0.0
Price Variance0.72
Neurogene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Neurogene technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Neurogene trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Neurogene Technical Analysis

Indicator
Time Period
Execute Indicator
The output start index for this execution was one with a total number of output elements of sixty. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Neurogene volatility. High ATR values indicate high volatility, and low values indicate low volatility.

About Neurogene Technical Analysis

The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Neurogene on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Neurogene based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Neurogene price pattern first instead of the macroeconomic environment surrounding Neurogene. By analyzing Neurogene's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Neurogene's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Neurogene specific price patterns or momentum indicators. Please read more on our technical analysis page.
 2025 2026 (projected)
Payables Turnover2.191.54
Days Of Inventory On Hand14.8713.22

Neurogene February 17, 2026 Technical Indicators

Most technical analysis of Neurogene help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Neurogene from various momentum indicators to cycle indicators. When you analyze Neurogene charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Neurogene February 17, 2026 Daily Trend Indicators

Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Neurogene stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

Complementary Tools for Neurogene Stock analysis

When running Neurogene's price analysis, check to measure Neurogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurogene is operating at the current time. Most of Neurogene's value examination focuses on studying past and present price action to predict the probability of Neurogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurogene's price. Additionally, you may evaluate how the addition of Neurogene to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios